➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Harvard Business School
Moodys
Baxter

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

FORTOVASE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Fortovase patents expire, and when can generic versions of Fortovase launch?

Fortovase is a drug marketed by Hoffmann La Roche and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this compound. Additional details are available on the saquinavir profile page.

US ANDA Litigation and Generic Entry Outlook for Fortovase

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for FORTOVASE
International Patents:40
US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: 44
Clinical Trials: 8
Patent Applications: 2,404
Formulation / Manufacturing:see details
DailyMed Link:FORTOVASE at DailyMed
Drug patent expirations by year for FORTOVASE
Recent Clinical Trials for FORTOVASE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Saint Michael's Medical CenterPhase 3
Boehringer IngelheimPhase 1
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1

See all FORTOVASE clinical trials

US Patents and Regulatory Information for FORTOVASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FORTOVASE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997   Start Trial   Start Trial
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997   Start Trial   Start Trial
Hoffmann La Roche FORTOVASE saquinavir CAPSULE;ORAL 020828-001 Nov 7, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for FORTOVASE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432695 96C0044 Belgium   Start Trial PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0034432 96C0048 Belgium   Start Trial PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695 32/1996 Austria   Start Trial PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695 C970013 Netherlands   Start Trial PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Moodys
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.